Skip to content

Effect of omega-3 on Allergy prevention

Effect of Fish Oil on the level of Interferon-Gamma in breast milk of atopic mothers

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT2017052234082N1
Enrollment
94
Registered
2017-07-03
Start date
2016-01-21
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allergy. Allergy, unspecified

Interventions

Intervention 1: Intervention group: Allergic mothers who had met inclusion criteria, received 1000mg omega-3 softgel contained 180mg EPA and 120mg DHA and was Mercury free (produced by Daana Pharmaceu
Treatment - Drugs
Intervention group: Allergic mothers who had met inclusion criteria, received 1000mg omega-3 softgel contained 180mg EPA and 120mg DHA and was Mercury free (produced by Daana Pharmaceutical Company OM
Control group: Allergic mothers who had met inclusion criteria, received placebo capsule contained 70% amylum and 30% Dicalcium phosphate (prepared in the School of Pharmacy of Isfahan University of M

Sponsors

Isfahan university of medical sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 40 Years

Inclusion criteria

Inclusion criteria: The inclusion criteria for atopic mothers: age of 18-40 years, gestational age of more than 37 weeks, and having a healthy singleton neonate with birth weight of more than 2500 grams. Exclusion criteria: history of smoking, history of using anti-inflammatory medications during pregnancy, having inflammatory and autoimmune diseases, consumption of fish and seafood more than two times a week during pregnancy. The exclusion criteria for infants: feeding with formula or any supplementary food during the trial (first 4 months of life), using anti-inflammatory drug during the study, clinical manifestations of allergy to fish in mothers, drug reaction in mothers and low compliance to continue the study.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Gamma Interferon. Timepoint: 4 months after starting the study. Method of measurement: ELISA kit.

Secondary

MeasureTime frame
Height- Weight- Head Circumference. Timepoint: at the beginning of study - 2months after beginning of study- 4months after beginning of study. Method of measurement: tape measure- scale.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Sara Saraeian

Isfahan university of medical sciences

research@mui.ac.ir+98 31 3668 0048

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026